Efficacy, Safety and Immunogenicity in Randomized, Double-Blind (DB) and OpenLabel Extension (OLE) Studies Comparing FKB327, an Adalimumab Biosimilar, with the Adalimumab Reference Product (Humira (R); RP) in Patients (pts) with Active Rheumatoid Arthritis (RA) Genovese, M. C., Glover, J., Matsunaga, N., Chisholm, D., Alten, R. WILEY. 2017

View details for Web of Science ID 000411824106303